The Future of Lymphoma Research, part 2
Lymphoma research is moving forward in several distinct ways. The Coalition of Cancer Cooperative Groups highlights a few more potential successes.
Immunotherapy
Many new antibodies are being developed that boost the body’s natural defenses against cancer. Some use antibodies that attach to the surface of tumor cells. Some have radioactive substances attached that can direct radiation treatment to the lymphoma. This form of treatment is known as radioimmunotherapy.
Targeted therapies
There are many new targeted treatments for lymphoma in early clinical trials and under evaluation in the laboratory. Targeted therapies are drugs that have been developed against specific genes or proteins within the lymphoma cells that are thought to be important in the development of cancer. It is hoped that because these drugs are directed against very specific targets that found only in lymphoma cells, they will have fewer side effects than chemotherapy or radiation therapy.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
